Medigen Vaccine Biologics Corporation (6547.TWO)

TWD 34.1

(-1.45%)

Market Cap (In TWD)

11.2 Billion

Revenue (In TWD)

389.62 Million

Net Income (In TWD)

-1.15 Billion

Avg. Volume

1.08 Million

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
33.7-70.8
PE
-
EPS
-
Beta Value
0.75
ISIN
TW0006547003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Leo Lee
Employee Count
-
Website
https://www.medigenvac.com
Ipo Date
2015-09-16
Details
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.